Literature DB >> 9012401

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

C Sachse1, J Brockmöller, S Bauer, I Roots.   

Abstract

Cytochrome P450 2D6 (CYP2D6) metabolizes many important drugs. CYP2D6 activity ranges from complete deficiency to ultrafast metabolism, depending on at least 16 different known alleles. Their frequencies were determined in 589 unrelated German volunteers and correlated with enzyme activity measured by phenotyping with dextromethorphan or debrisoquine. For genotyping, nested PCR-RFLP tests from a PCR amplificate of the entire CYP2D6 gene were developed. The frequency of the CYP2D6*1 allele coding for extensive metabolizer (EM) phenotype was .364. The alleles coding for slightly (CYP2D6*2) or moderately (*9 and *10) reduced activity (intermediate metabolizer phenotype [IM]) showed frequencies of .324, .018, and .015, respectively. By use of novel PCR tests for discrimination, CYP2D6 gene duplication alleles were found with frequencies of .005 (*1x2), .013 (*2x2), and .001 (*4x2). Frequencies of alleles with complete deficiency (poor metabolizer phenotype [PM]) were .207 (*4), .020 (*3 and *5), .009 (*6), and .001 (*7, *15, and *16). The defective CYP2D6 alleles *8, *11, *12, *13, and *14 were not found. All 41 PMs (7.0%) in this sample were explained by five mutations detected by four PCR-RFLP tests, which may suffice, together with the gene duplication test, for clinical prediction of CYP2D6 capacity. Three novel variants of known CYP2D6 alleles were discovered: *1C (T1957C), *2B (additional C2558T), and *4E (additional C2938T). Analysis of variance showed significant differences in enzymatic activity measured by the dextromethorphan metabolic ratio (MR) between carriers of EM/PM (mean MR = .006) and IM/PM (mean MR = .014) alleles and between carriers of one (mean MR = .009) and two (mean MR = .003) functional alleles. The results of this study provide a solid basis for prediction of CYP2D6 capacity, as required in drug research and routine drug treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9012401      PMCID: PMC1712396     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  30 in total

1.  Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.

Authors:  R Tyndale; T Aoyama; F Broly; T Matsunaga; T Inaba; W Kalow; H V Gelboin; U A Meyer; F J Gonzalez
Journal:  Pharmacogenetics       Date:  1991-10

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

3.  Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population.

Authors:  J A Agúndez; M C Ledesma; J M Ladero; J Benítez
Journal:  Clin Pharmacol Ther       Date:  1995-03       Impact factor: 6.875

4.  Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.

Authors:  F Broly; A Gaedigk; M Heim; M Eichelbaum; K Morike; U A Meyer
Journal:  DNA Cell Biol       Date:  1991-10       Impact factor: 3.311

5.  Cloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon.

Authors:  B Evert; E U Griese; M Eichelbaum
Journal:  Pharmacogenetics       Date:  1994-10

6.  Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls.

Authors:  T Tefre; A K Daly; M Armstrong; J B Leathart; J R Idle; A Brøgger; A L Børresen
Journal:  Pharmacogenetics       Date:  1994-04

7.  Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.

Authors:  R Saxena; G L Shaw; M V Relling; J N Frame; D T Moir; W E Evans; N Caporaso; B Weiffenbach
Journal:  Hum Mol Genet       Date:  1994-06       Impact factor: 6.150

8.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.

Authors:  I Johansson; E Lundqvist; L Bertilsson; M L Dahl; F Sjöqvist; M Ingelman-Sundberg
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

9.  Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population.

Authors:  C M Masimirembwa; I Johansson; J A Hasler; M Ingelman-Sundberg
Journal:  Pharmacogenetics       Date:  1993-12

10.  An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution.

Authors:  A K Daly; J B Leathart; S J London; J R Idle
Journal:  Hum Genet       Date:  1995-03       Impact factor: 4.132

View more
  186 in total

1.  Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.

Authors:  K J Aitchison; J Munro; P Wright; S Smith; A J Makoff; C Sachse; P C Sham; R M Murray; D A Collier; R W Kerwin
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Development and characterization of a rapid and comprehensive genotyping assay to detect the most common variants in cytochrome P450 2D6.

Authors:  L A Scarlett; S Madani; D D Shen; R J Ho
Journal:  Pharm Res       Date:  2000-02       Impact factor: 4.200

3.  CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype.

Authors:  S Panserat; L Sica; N Gérard; H Mathieu; E Jacqz-Aigrain; R Krishnamoorthy
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

4.  Mining SNPs from EST databases.

Authors:  L Picoult-Newberg; T E Ideker; M G Pohl; S L Taylor; M A Donaldson; D A Nickerson; M Boyce-Jacino
Journal:  Genome Res       Date:  1999-02       Impact factor: 9.043

5.  Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.

Authors:  T Kubota; Y Yamaura; N Ohkawa; H Hara; K Chiba
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

Review 6.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Authors:  Leif Bertilsson; Marja-Liisa Dahl; Per Dalén; Ayman Al-Shurbaji
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

Review 7.  Development of analytical technology in pharmacogenetic research.

Authors:  Ann K Daly
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-09-25       Impact factor: 3.000

8.  Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver.

Authors:  Z E Wilson; A Rostami-Hodjegan; J L Burn; A Tooley; J Boyle; S W Ellis; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 9.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

10.  Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.

Authors:  Muriel Noetzli; Monia Guidi; Karsten Ebbing; Stephan Eyer; Laurence Wilhelm; Agnès Michon; Valérie Thomazic; Ioana Stancu; Abdel-Messieh Alnawaqil; Christophe Bula; Serge Zumbach; Michel Gaillard; Panteleimon Giannakopoulos; Armin von Gunten; Chantal Csajka; Chin B Eap
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.